Sector revisions Gilead Sciences, Inc.

Equities

Market Closed - Nasdaq Other stock markets 21:00:00 15/12/2025 GMT			5-day change	1st Jan Change
119.78 ^USD	+0.14%		-1.16%	+29.67%

12-15	Gilead HIV combo of bictegravir & lenacapavir hits phase 3 goal	RE
12-15	Wolfe Research Adjusts Gilead Sciences PT to $150 From $140, Maintains Outperform Rating	MT

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. Revenue rev.	4m. EPS revision	4m. Revenue rev.	1y. EPS revision	1y. Revenue rev.	Visibility	Nbr of analysts
	GILEAD SCIENCES, INC.							26
	ELI LILLY AND COMPANY							27
	JOHNSON & JOHNSON							24
	ABBVIE INC.							28
	ROCHE HOLDING AG							18
	ASTRAZENECA PLC							19
	NOVARTIS AG							19
	MERCK & CO., INC.							26
	NOVO NORDISK A/S							20
	AMGEN INC.							27
	PFIZER INC.							24
	SANOFI							21
	VERTEX PHARMACEUTICALS INCORPORATED							25
	BRISTOL-MYERS SQUIBB COMPANY							22
	GSK PLC							18
	CHUGAI PHARMACEUTICAL CO., LTD.							14
	JIANGSU HENGRUI PHARMACEUTICALS CO.,LTD							18
	ALNYLAM PHARMACEUTICALS, INC.							24
	TAKEDA PHARMACEUTICAL COMPANY LIMITED							14
	Average							22
	Weighted average by Cap.							23